Doxifluridine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Doxifluridine
Accession Number
DB12947
Type
Small Molecule
Groups
Investigational
Description

Doxifluridine has been investigated for the treatment of Stomach Cancer.

Structure
Thumb
Synonyms
Not Available
External IDs
RO 219738 / RO-219738
Categories
UNII
V1JK16Y2JP
CAS number
3094-09-5
Weight
Average: 246.1924
Monoisotopic: 246.065199677
Chemical Formula
C9H11FN2O5
InChI Key
ZWAOHEXOSAUJHY-ZIYNGMLESA-N
InChI
InChI=1S/C9H11FN2O5/c1-3-5(13)6(14)8(17-3)12-2-4(10)7(15)11-9(12)16/h2-3,5-6,8,13-14H,1H3,(H,11,15,16)/t3-,5-,6-,8-/m1/s1
IUPAC Name
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-4-hydroxy-1,2-dihydropyrimidin-2-one
SMILES

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Doxifluridine.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Doxifluridine.Experimental
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Doxifluridine.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Doxifluridine.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Doxifluridine.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Doxifluridine.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Doxifluridine.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Doxifluridine.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Doxifluridine.Experimental
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Doxifluridine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Doxifluridine.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Doxifluridine.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Doxifluridine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Doxifluridine.Approved, Investigational
FingolimodDoxifluridine may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Doxifluridine.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Doxifluridine.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Doxifluridine.Experimental
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Doxifluridine.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Doxifluridine.Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Doxifluridine.Experimental
LeflunomideThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Leflunomide.Approved, Investigational
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Doxifluridine.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Natalizumab.Approved, Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Doxifluridine.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Doxifluridine.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Doxifluridine.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Doxifluridine.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Doxifluridine.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Doxifluridine.Experimental
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Doxifluridine.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Doxifluridine.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Doxifluridine.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Doxifluridine.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Doxifluridine.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Doxifluridine.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Doxifluridine.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Doxifluridine.Approved, Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Doxifluridine.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Doxifluridine.Investigational
TofacitinibDoxifluridine may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Doxifluridine.Approved, Investigational
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Doxifluridine.Approved
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Doxifluridine.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB60406
KEGG Compound
C12739
PubChem Compound
18343
PubChem Substance
347829090
ChemSpider
17322
BindingDB
50132295
ChEBI
31521
ChEMBL
CHEMBL1130

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentMalignant Neoplasm of Stomach2
4CompletedSupportive CareMalignant Neoplasm of Stomach1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility5.36 mg/mLALOGPS
logP-0.82ALOGPS
logP-0.8ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)6.2ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area102.59 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity51.55 m3·mol-1ChemAxon
Polarizability21.06 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 5'-deoxyribonucleosides. These are nucleosides in which the oxygen atom at the 5'position of the ribose moiety has been replaced by another atom. The nucleobases here are limited to purine, pyrimidine, and pyridine derivatives.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
5'-deoxyribonucleosides
Sub Class
Not Available
Direct Parent
5'-deoxyribonucleosides
Alternative Parents
Glycosylamines / Pyrimidones / Halopyrimidines / Aryl fluorides / Hydropyrimidines / Vinylogous amides / Tetrahydrofurans / Heteroaromatic compounds / Ureas / Secondary alcohols
show 9 more
Substituents
5'-deoxyribonucleoside / Glycosyl compound / N-glycosyl compound / Halopyrimidine / Pyrimidone / Aryl fluoride / Aryl halide / Pyrimidine / Hydropyrimidine / Heteroaromatic compound
show 20 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organofluorine compound, pyrimidine 5'-deoxyribonucleoside (CHEBI:31521)

Drug created on October 20, 2016 19:32 / Updated on November 09, 2017 05:15